Tarsus Buys iRenix in Deal Worth Up to $565 Million, Adds Late-Stage Eye Drug

기사 요약

Tarsus acquires iRenix to add IRX-101, with Phase 3 planned for 2027, as William Blair calls the deal a disciplined pipeline expansion.